Although the IL-6 trans-signaling via circulating sIL-6R and sgp130 has been reported to be associated with the risk or severity of inflammation-related diseases, such as cardiovascular events (CVE), metabolic syndrome, and COVID-19 infection (Weiss et al., 2013; Moreno Velasquez et al., 2015; Ritschel et al., 2016; Ziegler et al., 2019; Miri et al., 2021; Rodriguez-Hernandez et al., 2022; Li et al., 2023), no studies have been reported on the role of the IL-6 trans-signaling in cancer patients treated with ICIs. Here, IL6R is linked to metabolic syndrome.